Processa Pharmaceuticals (PCSA) Registration filing summary

Company overview and business model

• Clinical-stage biotech focused on expanding treatment options for autoimmune diseases; post-merger lead candidate VT-7208 is an oral, irreversible, CNS-penetrant BTK inhibitor.

• VT-7208 is being advanced for food allergy, chronic spontaneous urticaria and multiple sclerosis; legacy programs include PCS499, PCS12852 and PCS11T.

• Management cites unmet need, mechanistic rationale, clinical precedent, defined regulatory pathways and commercial potential in selecting VT-7208 indications.

Financial performance and metrics

• A July 2026 private placement generated $200 million in gross proceeds before placement-agent and other offering expenses.

• The merger was accounted for as an asset acquisition; acquired VT-7208 in-process R&D was expensed at acquisition, with no goodwill recognized.

• Auditors' reports on both legacy and Vidya financial statements expressed substantial doubt about each entity's ability to continue as a going concern.

Use of proceeds and capital allocation

• No proceeds from resale of the registered shares will go to the issuer; selling stockholders receive resale proceeds.

• The issuer bears registration costs, while selling stockholders generally bear their own brokerage, legal, accounting, tax and sale expenses.

• The prior $200 million private placement was completed alongside the Vidya merger; proceeds were not designated for a specific use in this resale filing.